[Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma]

With the advent of new drugs, the treatment outcome of multiple myeloma (MM) has dramatically improved. However, cure for MM has been difficult to attain, and the prognosis of cases resistant to various treatments remains extremely poor. In March 2021, the United States Food and Drug Administration approved idecabtagene vicleucel (Ide-cel) -a B-cell maturation antigen-targeted chimeric antigen receptor (CAR) T-cell therapy -for the treatment of patients with relapsed/refractory MM. The Japanese Ministry of Health, Labor and Welfare approved Ide-cel in December 2021, and CAR T-cell therapy for MM will soon be available for clinical use. This review highlights the latest evidence regarding CAR T-cell therapy for MM.